Compare AMTX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | XGN |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 110.7M |
| IPO Year | 2023 | 2014 |
| Metric | AMTX | XGN |
|---|---|---|
| Price | $1.14 | $8.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $13.38 | $10.57 |
| AVG Volume (30 Days) | ★ 694.5K | 336.5K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | N/A |
| Revenue This Year | $24.86 | $11.02 |
| Revenue Next Year | $44.09 | $10.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.14 | $2.59 |
| 52 Week High | $3.80 | $10.84 |
| Indicator | AMTX | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 56.14 |
| Support Level | N/A | $7.81 |
| Resistance Level | $1.87 | $8.94 |
| Average True Range (ATR) | 0.10 | 0.53 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 3.66 | 76.23 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.